The efficacy and safety of tocilizumab for refractory systemic juvenile idiopathic arthritis in China

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17011391

Enrollment

Unknown

Registered

2017-05-12

Start date

2016-09-01

Completion date

Unknown

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic juvenile idiopathic arthritis

Interventions

tocilizumab group:tocilizumab

glucocorticoid group:glucocorticoid

Eligibility

Sex/Gender

All

Age

2 Years to 16 Years

Inclusion criteria

Inclusion criteria: Eligible patients aged 2 to 16 years, with a diagnosis of sJIA according to the International League of Associations for Rheumatology criteria. Refractory sJIA is defined as who showed an inadequate response to NSAIDs (fever present after treatment with stable doses of NSAIDs for 2 weeks), were dependent on glucocorticoids (symptoms were aggravated or relapsed when the glucocorticoid dose was reduced), or showed no response to glucocorticoid therapy were included.

Exclusion criteria

Exclusion criteria: Acute or chronic infection (including tuberculosis), tumors, cardiac insufficiency, and other chronic diseases were excluded prior to administration of tocilizumab.

Design outcomes

Primary

Measure	Time frame
Juvenile Arthritis Disease Activity Score 27;inflammation index (ESR, CRP);	—

Countries

China

Contacts

Public ContactXuemei Tang

Children's Hospital of Chongqing Medical University

tangxuemei2008@163.com+86 13012352441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026